NDABUCCAL, SUBLINGUALFILM
Approved
Apr 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Adrenergic alpha2-Agonists
Pharmacologic Class:
Central alpha-2 Adrenergic Agonist
Clinical Trials (5)
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
Started Jul 2025
10 enrolled
Alcohol Use Disorder (AUD)Post Traumatic Stress Disorder (PTSD)
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
Started Oct 2024
200 enrolled
Breast Cancer
Postoperative Dexmedetomidine in Prevention of Postoperative Delirium
Started Nov 2023
287 enrolled
Delirium in Old AgeAnesthesia; Adverse Effect
Different Administration Routes of Dexmedetomidine on Postoperative Delirium
Started Aug 2023
120 enrolled
DexmedetomidinePostoperative DeliriumGeneral Anesthesia
Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study
Started Nov 2021
10 enrolled
Alcohol Use Disorder (AUD)Post Traumatic Stress Disorder (PTSD)
Loss of Exclusivity
LOE Date
Jan 12, 2043
205 months away
Patent Expiry
Jan 12, 2043
Exclusivity Expiry
Nov 19, 2028